Compare Abbott Laboratories (ABT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Summit Therapeutics Inc — how do they compare? Abbott Laboratories trades at $112.05 (market cap $191.92B), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Abbott Laboratories is far larger — about 15.9× Summit Therapeutics Inc's market cap, and Abbott Laboratories pays a 2.27% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABT | SMMT | |
|---|---|---|
Market Cap | $191.92B | $12.06B |
Sector | Health | Health |
52-Week High | $136.62 | $26.98 |
52-Week Low | $82.57 | $12.55 |
Enterprise Value | $218.92B | $11.39B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.02% with strong analyst support (75.6% buy ratings) and a $120.70 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026. Fundamentals remain solid with $44.33B revenue, 11.65% net margin, and improving cash flow trends. Recent CE Mark approval for Libre Duo glucose-ketone sensors highlights innovation momentum.
ABT presents a compelling investment case with strong fundamentals, positive analyst sentiment, and innovative product pipeline. Key risks include competitive pressures in medical devices and potential macroeconomic headwinds affecting healthcare spending. The stock's current valuation at 35.15 P/E appears reasonable given growth prospects and dividend stability.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
